Request Demo

Last update 03 Dec 2025

Dronabinol

Last update 03 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-delta9-trans-Tetrahydrocannabinol, 1-trans-delta-9-Tetrahydrocannabinol, 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [37]

Target

Action

agonists

Mechanism

CB agonists(Cannabinoid receptor agonists)

Therapeutic Areas

Other DiseasesNervous System DiseasesDigestive System Disorders+ [2]

Active Indication

AnorexiaNauseaVomiting+ [7]

Inactive Indication

Alzheimer DiseaseDepressive DisorderMultiple Sclerosis+ [1]

Originator Organization

AbbVie, Inc.

Active Organization

Avicanna, Inc.

Vertanical GmbH

Tetra Bio-Pharma, Inc.

+ [4]

Inactive Organization

Unimed Pharmaceutical, Inc.Benuvia Therapeutics, Inc.

Solvay SA

+ [1]

License Organization

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (31 May 1985),

AnorexiaNauseaVomiting

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS Registry1972-08-3

343

Clinical Trials associated with Dronabinol

NCT06956014

/ Not yet recruitingPhase 3

Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Start Date01 Mar 2026

Sponsor / Collaborator

Vertanical GmbH

NCT07224698

/ Not yet recruitingPhase 2IIT

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Start Date01 Feb 2026

Sponsor / Collaborator

Multidisciplinary Association for Psychedelic Studies

NCT05067387

/ Not yet recruitingPhase 1IIT

Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women

The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.

Start Date15 Jan 2026

Sponsor / Collaborator

University of California, Los Angeles

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

13,721

Literatures (Medical) associated with Dronabinol

01 Feb 2026·FORENSIC SCIENCE INTERNATIONAL

Drug use pattern of suspected drug-influenced drivers in Hungary (2019–2023)

Article

Author: Institóris, László ; Süvegh, Gábor ; Kereszty, Éva M ; Kovács, Katalin ; Hidvégi, Előd ; Rárosi, Ferenc ; Berkecz, Róbert ; Sija, Éva

Between 2019 and 2023, blood and urine samples of 6229 suspected impaired drivers were analysed, with a positivity rate of 91.5 %. Classical illicit drugs were detected in 4693 drivers, medicines in 850 drivers, stimulant new psychoactive substances (sNPS) in 928 drivers and synthetic cannabinoid receptor agonists (SCRAs) in 657 drivers. The consumption of cannabis, N-ethyl-norpentedron, and N-ethyl-hexedrone increased significantly over time, while the consumption of five SCRAs declined. These changes were concordant with the seizure data for the entire country. 74.2 % of drug-positive drivers were deemed impaired. Impairment was determined by fixed concentration limits in 3538 cases, multi-drug use in 507 cases, and clinical symptoms (when only one active substance with no impairment limit was present in the blood) in 217 cases. To evaluate clinical tests, the prevalence of positive and negative clinical findings was compared for amphetamine/methamphetamine, THC, MDMA, alprazolam, and clonazepam above and below their fixed concentration limits. Only alprazolam showed a significantly higher frequency of positive clinical signs above the limit. This finding suggests that the current protocol of medical examination in Hungary is inadequate for diagnosing impairment when only one active substance without a defined threshold is detected in the blood. Given that sNPS was detected in 24.1 % of drivers, the medical investigation system requires a major revision. The aim of this study was to investigate the illicit and licit drug consumption of suspected impaired drivers in Hungary and to present the disadvantages of the system currently used for diagnosing and proving impairment.

01 Feb 2026·FORENSIC SCIENCE INTERNATIONAL

Detection and quantification of selected cannabinoids in hair samples by liquid-liquid extraction and LC-MS/MS

Article

Author: Antunes, Mónica ; Gallardo, Eugenia ; Franco, João M ; Simões, Susana ; Barroso, Mário ; Fonseca, Suzana

Cannabis remains the most used illicit drug worldwide, with rising use linked to medical and recreational decriminalization. This has driven the development of analytical techniques to detect cannabinoids in biological matrices. Hair offers key advantages due to its non-invasive collection, extended detection window, stability, and easy storage. This study presents the development and validation of a robust method for extracting natural cannabinoids from hair, following ANSI/ASB 2019, FDA, and Society of Hair Testing guidelines. Hair samples were washed with methanol and cut into small pieces. Approximately 20 mg of hair was incubated with 1 M NaOH and methanol (30 min, 50 °C). The mixture was acidified with acetic acid and underwent liquid-liquid extraction using hexane/ethyl acetate (90/10, v/v). The organic phase was evaporated and reconstituted in 1-pentanol/methanol (50/50, v/v). Analysis was conducted by LC-MS/MS using multiple reaction monitoring (MRM) and triple-stage mass spectrometry (MS³). The method was selective, specific, precise, and linear, with working ranges of 5-2000 pg/mg for THC, CBN, and CBD; 50-2000 pg/mg for THC-OH; and 0.2-20 pg/mg for THC-COOH. Ion suppression was observed but did not affect sensitivity, with LLOQs and LODs from 0.2 to 50 pg/mg. Over 25 hair samples from university students tested positive for cannabis. THC ranged from 5.9 to 2430.7 pg/mg; one sample had THC-OH above LLOQ (61.4 pg/mg); THC-COOH ranged from 0.3 and 36.4 pg/mg; CBN from 5.7 to 461.0 pg/mg; and CBD from 5.7 to 850.2 pg/mg. Results aligned with self-reported use, confirming the method's forensic suitability.

01 Jan 2026·TALANTA

A novel electrochemical method for detecting synthetic cannabinoids in e-cigarette and biological samples using a lab-made electrode

Article

Author: Arantes, Luciano C ; Melo, Larissa M A ; Dos Santos, Wallans T P ; Souza, Karla A O ; Barroso, Cecília N F ; Marton, Marian ; Aranha, Lívia M S ; Vojs, Marian ; Costa, Jose L ; Pereira, Thiago F L

Synthetic Cannabinoid Receptor Agonists (SCRAs) are a class of Novel Psychoactive Substances (NPS) that interact with the same receptors (CB1 and CB2) as delta-9-tetrahydrocannabinol (THC). The identification of SCRAs, such as AB-CHMINACA and MDMB-4en-PINACA, is of significant forensic and toxicological interest due to their widespread consumption in several countries and their potential involvement in overdose cases resulting from their high potency, posing a serious public health and safety concern. Currently, no standardized screening methods exist for the detection of SCRAs in forensic and toxicological contexts. This study introduces a novel electroanalytical method that combines laboratory-fabricated boron-doped diamond screen-printed electrodes (SP/BDDE) with square-wave adsorptive stripping voltammetry (SWAdSV) for the detection of AB-CHMINACA and MDMB-4en-PINACA in e-cigarette samples and real biological matrices. For the first time, the electrochemical behavior of these SCRAs is comprehensively investigated, and all their redox processes (P_c1/P_a2 and P_a3) are utilized for selective and accurate identification. The proposed method exhibited a wide linear range (20-100 μM for AB-CHMINACA and 20-70 μM for MDMB-4en-PINACA) with a low detection limit of 0.282 μM, making it highly suitable for forensic applications involving seized samples and toxicological analyses of biological specimens. The stability of the electrochemical response was assessed, with SP/BDDE showing relative standard deviations (RSD) below 10 % for E_p and I_p. Interference studies confirmed the high selectivity of the method for SCRA detection. AB-CHMINACA and MDMB-4en-PINACA were successfully identified in e-cigarette and biological samples, with recovery rates approaching 100 %, indicating minimal matrix effects in these complex samples. Therefore, the proposed method proves to be a promising, rapid, and selective screening approach for the detection of SCRAs in forensic and toxicological scenarios, as a screening test.

541

News (Medical) associated with Dronabinol

02 Dec 2025

·www.globenewswire.com

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the “Target Company"). Pursuant to the Term Sheet, NeuroThera will acquire a 55% equity interest in the Target Company from certain selling shareholders of the Target Company (the “Selling Shareholders”), calculated on a post transaction fully diluted basis, in consideration for the issuance to the Selling Shareholders of that amount of common shares, no par value per share, of NeuroThera equal to 40% of NeuroThera’s share capital, calculated on a non-diluted basis (the “Acquisition”). By harnessing the principles of quantum computing, bio data can be stored, manipulated, and analyzed far more efficiently in comparison to the existing technologies, potentially revolutionizing the field through accelerated processing and enhanced insights. This innovative approach is based on key quantum phenomena such as superposition, entanglement, and inherent parallelism to deliver faster computations and superior machine learning performance. In turn, it strives to redefine clinical trials via quantum intelligence, seamlessly integrating quantum computing with bioinformatics and clinical data science to potentially unlock precision and speed in medical research and development. The Acquisition remains subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions. There can be no assurance that any definitive agreement will be entered into or that the transaction will be completed on the terms described, or at all. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. About Neurothera Labs Inc. NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the benefits and advantages of quantum computing and that the Acquisition is subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

Acquisition

01 Dec 2025

·www.globenewswire.com

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (“GERD”). Building on Xylo 's successful commercialization in Greater China through licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, of which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories, such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock substantial revenue streams. Under the terms of the binding term sheet, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual property rights, mainly associated with the MUSE™ system, from Xylo. Subject to negotiating and signing definitive agreements for the acquisition, in consideration for these acquired assets, SciSparc shall issue to Xylo, upon the closing of definitive agreements (the “Closing”), an amount of ordinary shares of the Company, which shall represent as of the Closing date, 19.99% of the issued and outstanding share capital of SciSparc (the “Issued Shares”). SciSparc may elect at its sole discretion to issue, in lieu (in whole or in part) of the Issued Shares, pre-funded warrants to purchase ordinary shares. According to a May 2025 market research report by MarkNtel Advisors, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030. This press release does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and such securities may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE TM system from Xylo; the consideration for the acquired assets to be paid to Xylo at Closing; the Company’s plans to replicate Xylo’s licensing and distribution model from Greater China to other territories, such as North America, Europe and Latin America; the Company’s plans to pursue exclusive partnerships with leading regional distributors to accelerate commercialization and unlock substantial revenue streams; and the expected value and growth of the global GERD device market. The acquisition of the intellectual property assets described in this press release is subject to the Company and Xylo negotiating and agreeing definitive agreements. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055

License out/inAcquisition

26 Nov 2025

·www.globenewswire.com

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. ("Xylo”). The MUSE™ system is a single-use, innovative endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (“GERD”). Building on Xylo 's successful commercialization in Greater China through licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, of which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories, such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock substantial revenue streams. Under the terms of the binding term sheet, SciSparc will acquire the complete portfolio of patents, trademarks, know-how, and related intellectual property rights, mainly associated with the MUSE™ system, from Xylo. Subject to negotiating and signing definitive agreements for the acquisition, in consideration for these acquired assets, SciSparc shall issue to Xylo, upon the closing of definitive agreements (the “Closing”), an amount of ordinary shares of the Company, which shall represent as of the Closing date, 19.99% of the issued and outstanding share capital of SciSparc (the “Issued Shares”). SciSparc may elect at its sole discretion to issue, in lieu (in whole or in part) of the Issued Shares, pre-funded warrants to purchase ordinary shares. According to a May 2025 market research report by MarkNtel Advisors, the global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030. This press release does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and such securities may not be offered or sold within the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses: the expected acquisition of a portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE TM system from Xylo; the consideration for the acquired assets to be paid to Xylo at Closing; the Company’s plans to replicate Xylo’s licensing and distribution model from Greater China to other territories, such as North America, Europe and Latin America; the Company’s plans to pursue exclusive partnerships with leading regional distributors to accelerate commercialization and unlock substantial revenue streams; and the expected value and growth of the global GERD device market. The acquisition of the intellectual property assets described in this press release is subject to the Company and Xylo negotiating and agreeing definitive agreements. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055

License out/in

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	United States	Alkem Laboratories Ltd.	31 May 1985
Nausea	United States	Alkem Laboratories Ltd.	31 May 1985
Vomiting	United States	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	Canada	Tetra Bio-Pharma, Inc.	01 May 2023
Sleep Apnea, Obstructive	Phase 3	United States	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Low Back Pain	Phase 3	Germany	Vertanical GmbH	07 Jul 2021
Decrease in appetite	Phase 3	Europe	Solvay SA	15 Feb 2007
Tourette Syndrome	Phase 2	United States	SciSparc Ltd.	01 Feb 2017
Alzheimer Disease	Phase 2	United States	Unimed Pharmaceutical, Inc.	29 Jul 1996
Depressive Disorder	Phase 2	United States	Unimed Pharmaceutical, Inc.	29 Jul 1996
Parkinson Disease	Preclinical	Canada	Pike Therapeutics, Inc.	01 Nov 2024
Cognition Disorders	Preclinical	Israel	Therapix Biosciences Ltd /Non-Pain Assets/	13 May 2018
Cachexia	Discovery	South America	Avicanna, Inc.	14 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05610813 (Pubmed \| Pain Ther)	Phase 3	Low Back Pain	384	VER-01	xwypqreebf(qoatxkilii) = qlwbmerlxx mdbhiczpoq (fuqxjseyac ) View more	Positive	30 Sep 2025
				Opioids	cnzbfumfom(puxmlffxbb) = uspzgqlobe bcigcagsmi (ebpxwthhjl ) View more
NCT05477875 (CTgov)	Phase 2	Myopia \| Hyperopia \| Pain, Postoperative	35	Cannabidiol (Cannabidiol)	ctrsvqrajt(klpvbgxxra) = vgmhqpzpiv rbkzahayci (wwljwueinz, 0.95) View more	-	07 Aug 2025
				Tylenol T3 (Tylenol T3)	ctrsvqrajt(klpvbgxxra) = gogabwahez rbkzahayci (wwljwueinz, 0.89) View more
NCT05820685 (DOPE, CTgov)	Phase 4	Pain	484	Standard of Care (Standard of Care)	gxpptujpxb(gwgnddgtwx) = sxipqbhogu mssbiwwsas (sqobmkzepo, cscmxlnihs - etorchazps) View more	-	11 Jun 2025
				Standard of Care+Dronabinol (Standard of Care + Dronabinol)	gxpptujpxb(gwgnddgtwx) = fptaymqlac mssbiwwsas (sqobmkzepo, tnnwffdgss - wkkedjrknr) View more
NCT02792257 (THC-AD, CTgov)	Phase 2	Alzheimer Disease \| Agitation	84	Dronabinol (Dronabinol)	kagffchwln(djuugafbvz) = wmmjfuxybs pihevbchbb (ebflxluakb, 4.12) View more	-	09 May 2025
				Placebo (Placebo)	kagffchwln(djuugafbvz) = uyjkmyrjdu pihevbchbb (ebflxluakb, 4.18) View more
NCT03705559 (CTgov)	Phase 1	Marijuana Abuse	10	Placebo (Placebo/Placebo)	sgecxeuecz(ehhhjfuech) = yhbzhfcrph hiyqyhprwu (obdzherfya, 1.83) View more	-	10 Apr 2025
				Placebo+THC (THC 10mg/Placebo Opioid)	sgecxeuecz(ehhhjfuech) = kxbzadwkrq hiyqyhprwu (obdzherfya, 10.03) View more
NCT02817698 (CTgov)	Early Phase 1	Smoking \| Marijuana Abuse \| Unspecified drug dependence	25	cannabis	jzkuiguryh(yflitqjrpy) = lghlbhpdxd rjhikiswwy (khfbjnpnpn, rkogspjpjj - qmowhifnsy) View more	-	12 Dec 2024
NTIASD1 (Company_Website) Manual	Phase 1/2	Autism Spectrum Disorder	14	NTI164	fcqgxfvtwy(fuzvuidpcr) = hefgufluuq ngbtyzwfko (kxyepacevp )	Positive	01 Dec 2024
NCT03804840 (AIS, CTgov)	Early Phase 1	Thrombocytopenia 1	72	Placebo (Placebo)	jezoovstzq(kvktpqadec) = wgkmrahwpn rfxgagbssn (zwdbksmdqi, .07) View more	-	19 Sep 2024
				Dronabinol (7.5 mg THC)	jezoovstzq(kvktpqadec) = qsaezbjjrs rfxgagbssn (zwdbksmdqi, .09) View more
NCT03809546 (IDT, CTgov)	Early Phase 1	Thrombocytopenia 1	60	dextrose (Placebo)	cykhloxeik(gjbbpwwjus) = ncksblfror bqxyygdbde (yexjsocwev, 0.047) View more	-	03 Jul 2024
				Dronabinol (7.5 mg THC)	cykhloxeik(gjbbpwwjus) = koznfrevlm bqxyygdbde (yexjsocwev, 0.07) View more
NCT03699540 (CTgov)	Phase 1	Marijuana Abuse	10	Alcohol+THC (Inactive Alcohol / THC 0mg)	vzdovfdvjh(rvoumnogrk) = nghenkeljc lqqevhnpau (tdcorwctyo, 0.09) View more	-	03 Jul 2024
				Alcohol+THC (Inactive Alcohol / THC 15mg)	vzdovfdvjh(rvoumnogrk) = xfywiexrzy lqqevhnpau (tdcorwctyo, 0.09) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis